Welcome!

News Feed Item

Lilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathways At AACR 2014

INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

"Harnessing Breakthroughs – Targeting Cures" is the theme of this year's AACR meeting and one that is mirrored throughout Lilly's early-stage oncology research. Lilly's oncology pipeline is among the most robust across the pharmaceutical industry and includes a broad range of large and small molecules being investigated to treat a wide range of cancers including lung, breast, colorectal, gastric, liver and hematologic malignancies. Lilly research presented at AACR will represent early findings from several of those early-stage clinical agents.

Data from bemaciclib, Lilly's CDK4/6 inhibitor LY2835219 as a potential treatment for metastatic breast cancer, has been accepted as a late-breaking presentation that will be included at AACR's Clinical Trials Symposium and will be featured in an official AACR-sponsored press conference.

"The CDK4/6 pathway is one of the most commonly implicated pathways in all cancers, making it an important area for research," said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology. "The single-agent activity we've observed for bemaciclib is encouraging in this setting and we believe the data support the need for further development in metastatic breast cancer."

Lilly's B-Raf inhibitor LY3009120 will be highlighted at AACR's New Drugs on the Horizon special session where first data disclosures of promising, new anti-cancer compounds that target key pathways will occur. There will also be an oral presentation on Lilly's c-MET kinase inhibitor, LY2801653.

"As we gain a better understanding about the distinct tumor biologies and other individual characteristics that make one tumor different than another, we are able to apply this knowledge to our development of potential new cancer treatments, such as those we are presenting at AACR," said Dr. Gaynor. "Each step we take during early-stage research – both in the lab and on clinical trials – leads us toward the same overall goal: to increase the number of treatment options available to patients."

Select Lilly early-stage pipeline studies, along with the times and locations of their data sessions, are highlighted below.

bemaciclib (LY2835219)

  • Abstract #CT232: Clinical Trials Symposium: Monday, April 7, 2014 1:30 pm1:50 pm
    • Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
    • Author/Speaker: Amita Patnaik, M.D., FRCP(C)
    • Location: Room 25
    • Note: Abstract #CT232 to be presented at AACR press conference on April 6 at 7:30 am

B-Raf Inhibitor (LY3009120)

  • Abstract #7135: New Drugs on the Horizon Special Session: Sunday, April 6, 2014 3:45 pm to 4:10 pm
    • Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimer with activity against BRaf or Ras mutant tumor cells and minimal paradoxical activation
    • Author/Speaker: Sheng-Bin Peng, Ph.D.
    • Location: Room 29

c-MET Inhibitor (LY2801653)

  • Abstract #CT237: Clinical Trials Minisymposium: Monday, April 7, 2014 3:20 pm3:35 pm
    • Interim results of a first-in-human Phase I study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer
    • Author/Speaker: Jimmy Hwang, M.D.
    • Location: Room 29
  • Abstract #4403: Poster Presentation: Tuesday April 8, 2014 1:00 pm to 5:00 pm
    • Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
    • Author/Speaker: S. Betty Yan, Ph.D.
    • Location: Hall A-E, Section 24

FGFR Inhibitor (LY2874455)

  • Abstract #CT215: Poster Presentation: Monday, April 7, 2014 8:00 am to 12:00 pm
    • A Phase 1 Study of LY2874455, a Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Cancer
    • Author/Speaker: Dr. Jeanne Tie
    • Location: Hall A-E, Section 38

P-LLY

This press release contains forward-looking statements about the potential of LY2835219, LY2801653, LY3009120 and LY2874455 as treatments for various cancers and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results for these products will be consistent with study findings to date, that these products will receive regulatory approvals, or will prove to  be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Media Inquiries:


Keri McGrath, Lilly Oncology

Neil Hochman, TogoRun

317-370-8394 (mobile)

212-453-2067 (office) / 516-784-9089 (mobile)

Email: [email protected]

Email: [email protected]

 

Eli Lilly and Company logo

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

 

SOURCE Eli Lilly and Company

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
18th Cloud Expo, taking place June 7-9, 2016, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises are using some...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...
SoftLayer operates a global cloud infrastructure platform built for Internet scale. With a global footprint of data centers and network points of presence, SoftLayer provides infrastructure as a service to leading-edge customers ranging from Web startups to global enterprises. SoftLayer's modular architecture, full-featured API, and sophisticated automation provide unparalleled performance and control. Its flexible unified platform seamlessly spans physical and virtual devices linked via a world...
In his session at 18th Cloud Expo, Andrew Cole, Director of Solutions Engineering at Peak 10, will discuss how the newest technology advances are reducing the cost and complexity of traditional business continuity and disaster recovery solutions. Attendees will: Learn why having a full disaster recovery strategy is more important now than ever before Explore the key drivers of a successful disaster recovery solution Achieve measurable operational and business value from a disaster recovery ...
In his session at 18th Cloud Expo, Bruce Swann, Senior Product Marketing Manager at Adobe, will discuss how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects). Bruce Swann has more than 15 years of experience working with digital marketing disciplines like web analytics, social med...
SYS-CON Events announced today that 24Notion has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. 24Notion is full-service global creative digital marketing, technology and lifestyle agency that combines strategic ideas with customized tactical execution. With a broad understand of the art of traditional marketing, new media, communications and social influence, 24Notion uniquely understands how to con...
SYS-CON Events announced today that EastBanc Technologies will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. EastBanc Technologies has been working at the frontier of technology since 1999. Today, the firm provides full-lifecycle software development delivering flexible technology solutions that seamlessly integrate with existing systems – whether on premise or cloud. EastBanc Technologies partners with p...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
SYS-CON Events announced today that Hanu Software will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Leveraging best-in-class people, processes, and technologies, Hanu provides high-quality, high-value software development and business process outsourcing services to independent software vendors (ISVs) and enterprises.
The initial debate is over: Any enterprise with a serious commitment to IT is migrating to the cloud. But things are not so simple. There is a complex mix of on-premises, colocated, and public-cloud deployments. In this power panel at 18th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists will look at the present state of cloud from the C-level view, and how great companies and rock star executives can use cloud computing to meet their most ambitious and disruptive business ...
Many banks and financial institutions are experimenting with containers in development environments, but when will they move into production? Containers are seen as the key to achieving the ultimate in information technology flexibility and agility. Containers work on both public and private clouds, and make it easy to build and deploy applications. The challenge for regulated industries is the cost and complexity of container security compliance. VM security compliance is already challenging, ...